Lancet Neurol:GRN突变与额颞叶退化

2018-05-02 zhangfan MedSci原创

研究认为 TMEM106B以及GFRA2相关途径在额颞叶变性过程中发挥关键作用

GRN基因功能丧失突变会引起额颞叶变性(FTLD),突变患者一致存在TAR DNA结合蛋白43(TDP-43)病理亚型(FTLD-TDP A型),但不同患者发病年龄和临床表现存在差异,甚至家庭内部也是如此。近日研究人员就GRN突变携带人群潜在的疾病发病因素进行了考察。

本次研究分为发现、验证以及荟萃分析3个阶段。第1阶段中采用全基因组逻辑和线性回归分析考察GRN突变患者与无神经退行性疾病患者基因变异与疾病风险的关系,之后验证突变热点与疾病的关系,最后进行荟萃分析考察。采用mRNA表达研究评估GFRA2基因位点的全基因组显著变异对GFRA2表达的影响,采用ELISA研究GFRA2基因-蛋白效应,利用免疫共沉淀实验,检测GFRA2与颗粒蛋白前体抗原--丙谷蛋白的直接相互作用。

发现和验证阶段分别招募382和210名不相关症状性GRN突变患者,1146和1798名对照志愿者。未发现年龄与GRN基因变异之间的关系。研究发现TMEM106B(rs1990622,比值比0.54, 95% CI 0.46-0.63)以及8p21.3染色体GFRA2突变(rs36196656,比值比OR 1.49, 95% CI 1.30-1.71)与疾病风险显示相关。rs36196656等位基因可降低小脑组织中GFRA2mRNA浓度,ELISA显示血液中rs36196656与脑脊液颗粒蛋白前体抗原之间无相关性,但HEK293T细胞免疫共沉淀认为GFRA2与颗粒蛋白前体抗原存在直接相互作用。

研究认为 TMEM106B以及GFRA2相关途径在额颞叶变性过程中发挥关键作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000407, encodeId=c475200040ebd, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 18 03:35:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829611, encodeId=09e11829611e2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Sep 03 05:35:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615319, encodeId=aae3161531901, content=<a href='/topic/show?id=29ae826375' target=_blank style='color:#2F92EE;'>#GRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8263, encryptionId=29ae826375, topicName=GRN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f68619606350, createdName=ms7517674339485982, createdTime=Fri May 04 00:35:00 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-06-18 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000407, encodeId=c475200040ebd, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 18 03:35:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829611, encodeId=09e11829611e2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Sep 03 05:35:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615319, encodeId=aae3161531901, content=<a href='/topic/show?id=29ae826375' target=_blank style='color:#2F92EE;'>#GRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8263, encryptionId=29ae826375, topicName=GRN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f68619606350, createdName=ms7517674339485982, createdTime=Fri May 04 00:35:00 CST 2018, time=2018-05-04, status=1, ipAttribution=)]
    2018-09-03 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000407, encodeId=c475200040ebd, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 18 03:35:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829611, encodeId=09e11829611e2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Sep 03 05:35:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615319, encodeId=aae3161531901, content=<a href='/topic/show?id=29ae826375' target=_blank style='color:#2F92EE;'>#GRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8263, encryptionId=29ae826375, topicName=GRN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f68619606350, createdName=ms7517674339485982, createdTime=Fri May 04 00:35:00 CST 2018, time=2018-05-04, status=1, ipAttribution=)]